Tezacaftor?(VX-661) , 99% , 1152311-62-0
CAS NO.：1152311-62-0
Empirical Formula: C26H27F3N2O6
Molecular Weight: 520.5
MDL number: MFCD23106064
| Pack Size | Price | Stock | Quantity |
| 1mg | RMB789.60 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Boiling point: | 610.8±55.0 °C(Predicted) |
| Density | 1.49±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C , stored under nitrogen |
| solubility | ≥21.8 mg/mL in DMSO; insoluble in EtOH; ≥24.3 mg/mL in H2O |
| form | solid |
| pka | 13.99±0.20(Predicted) |
| color | White to yellow |
| InChIKey | MJUVRTYWUMPBTR-MRXNPFEDSA-N |
| SMILES | C1(C2=CC=C3OC(F)(F)OC3=C2)(C(NC2C(F)=CC3=C(C=2)C=C(C(C)(C)CO)N3C[C@@H](O)CO)=O)CC1 |
Description and Uses
Tezacaftor (VX-661) is an oral medication for cystic fibrosis (CF) developed by Vertex Pharmaceuticals. In a combination therapy formulation called Symdeko (tezacaftor plus ivacaftor), it is approved in the U.S. and Canada for CF patients, ages 12 and older, who have two copies of the F508del mutation in the CFTR gene and one minimal function mutation. Symdeko is approved and marketed in the EU as Symkevi.Tezacaftor is not approved as a stand-alone treatment, but as part of a combination therapy.
Tezacaftor is used as a combination therapy with Ivacaftor for the treatment of patients with cystic fibrosis.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
